Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Vivus gets development & marketing rights to Tanabe's TA-1790

29 Mar 2018

Executive Summary

Vivus (sexual dysfunction products) has licensed worldwide development and marketing rights--excluding Japan, China, and specific Pacific Rim countries--to Tanabe Seiyaku's (cardiovascular diseases) Phase I phosphodiesterase type 5 (PDE5) inhibitor TA-1790 (avanafil). The drug candidate treats male and female sexual dysfunction through oral and local administration.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By